Harlan Robins Sells 8,120 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 8,120 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.00, for a total value of $154,280.00. Following the sale, the insider directly owned 1,179,524 shares of the company’s stock, valued at approximately $22,410,956. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adaptive Biotechnologies Trading Down 6.5%

Shares of NASDAQ ADPT traded down $1.20 during mid-day trading on Wednesday, hitting $17.30. The company had a trading volume of 2,165,376 shares, compared to its average volume of 1,785,883. The stock’s 50-day moving average price is $17.17 and its 200-day moving average price is $15.15. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -32.04 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 1 year low of $6.26 and a 1 year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same period in the previous year, the firm posted ($0.22) EPS. The firm’s revenue was up 102.4% compared to the same quarter last year. As a group, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ADPT. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 7th. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Piper Sandler increased their price target on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.22.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several large investors have recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in shares of Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock worth $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC grew its holdings in Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after purchasing an additional 904 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Adaptive Biotechnologies by 3.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock valued at $355,000 after acquiring an additional 910 shares during the period. California State Teachers Retirement System grew its stake in Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after buying an additional 933 shares during the period. Finally, Captrust Financial Advisors grew its stake in shares of Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.